PHARSIGHT CORP. - 500 Beiträge pro Seite

[Jummi]

Diese Aktie wurde im letzten Biotech Report vorgestellt. Vielleicht hat jemand von euch weitere Infos. Die Fa soll Kosten der Pharmaunternehmen senken. Hört sich doch Interessant an oder???

ciao

[mastermh]

Hallo @ all!

Habe den Artikel im Biotech-Report ebenfalls gelesen und finde die Strategie / Idee super! Der Wert ist noch nicht lange am Markt und somit noch recht unbekannt! Ich würde mich auch freuen, wenn jeder der etwas zu Pharsight schreiben / posten kann sollte es hier in diesem ersten Thread zu diesem neuen Wert machen!

ciao mastermh

[Jummi]

Hey Mastermh!!!
Ich glaube wir sind die einzigen die sich mit diesem Wert beschäftigen und das eventuelle Potentzial, was in dieser Aktie steckt erkennen. Es würde mich freuen wenn auch andere Boardteilnehmer mal ihre Meinungen schreiben würden. Ich denke mal da gibt es noch viele Verbesserungsmöglichkeiten für die Optimierung der Forschungskosten.

Jummi

[Jummi]

Hey Mastermh!!!

PHARSIGHT ist in den USA um 9 Prozent geklettert. Ich denke mal die Umsätze sind für diesen Wert auch erst einmal ok. Vieleicht hast du schon weitere Infos. Danke für die Antwort.

ciau Jummi

[mastermh]

Hallo jummi!

Anscheinend ist der Wert bei den Boardteilnehmern zu riskant, oder einfach zu unbekannt! Viele großen Bios haben heute abgegeben, aber Pharsight konnte sich behaupten! Der Wert ist noch nicht gelaufen und somit steht auch keine Korrektur (m.M.) bevor! Ich schreibe nochmal, damit der Thread wieder nach oben kommt und somit vielleicht einige Infos zusammengekratzt werden können!!

ciao mastermh

[Jean_II]

Hab mir heute mal wieder eine Liste von neuen Biotechs zusammengestellt und werde diese mir jetzt nacheinander genauer anschauen, Pharsight ist auch dabei, könnte eine sehr interessante Chance sein!
Gruss Jean_II

[Jummi]

PHARSIGHT ANNOUNCES FIRST QUARTER RESULTS

MOUNTAIN VIEW, CA (Sept 19, 2000) -- Pharsight Corporation (Nasdaq: PHST) today reported financial results for the first quarter of fiscal 2001. For the quarter ended June 30, 2000, revenue increased 77% to $2.5 million, up from $1.4 million for the quarter ended June 30, 1999. The increase in revenue reported is due primarily to continuing increases in activity in both Pharsight’s product and consulting services.

The company reported a net loss for the quarter ended June 30, 2000 of $5.4 million, or ($1.39) per share, compared to a net loss of $2.5 million, or ($0.84) per share for the same period in 1999. The increase in net loss is primarily attributed to amortization of deferred stock compensation (non-cash) and expansion of staff and operations. Included in the first quarter, was a non-cash expense of $2.1 million or ($0.54) per share that is associated with the amortization of deferred stock compensation.

As of June 30, 2000, Pharsight had $11.4 million in cash, cash equivalents and marketable securities compared to $3.4 million at the end of the same period last year. On August 9, 2000, Pharsight completed its initial public offering resulting in the sale of 3,000,000 shares of common stock at a price of $10.00 per share that provided gross proceeds to the company of $30.0 million. The proceeds of the offering will be reflected in the company’s second quarter financials results.

Commenting on the first quarter financial results, Art Reidel, Pharsight’s president and chief executive officer, said, ``I am very pleased by our performance during the first quarter. The majority of this revenue came from repeat business with existing customers, reflecting their growing recognition of the value of Pharsight’s approach for accelerating the drug development process.

"We additionally signed several customer agreements in recent months. These included new relationships with a large pharmaceutical company in Japan and a prominent U.S. firm that raised our customer base with major pharmaceutical developers to 13 of the top 20 companies worldwide. We expect to continue this penetration over the coming months, as well as to convert additional tactical users of our products and services to companies who deploy the Pharsight approach across multiple development programs, on a strategic basis.

"We are also on track to release our Clinical Workbench product during fiscal third quarter. The Clinical Workbench is designed to enable users to test critical assumptions in clinical development by analyzing data on target populations, disease progression, current therapeutic approaches and characteristics of the potential market for relevant drugs. We have signed agreements with several health care providers, with which we are collaborating to develop the Pharsight Information Resource databases for use with this product. The first databases focus on diabetes and cardiovascular therapeutic areas.

"I’m especially proud of the world-class team that Pharsight has assembled covering all aspects of the clinical development process, whose expertise is increasingly being recognized by others within the pharmaceutical industry. In particular, I am pleased to announce that the American College of Clinical Pharmacology has chosen Jaap Mandema, Ph.D., our vice president and chief scientist, as the recipient of the 2000 ACCP Tanabe Young Investigator Award in recognition of his work in the area of population pharmacokinetics and pharmacodynamics."

Investors are invited to listen to the webcasted discussion by Pharsight management of this earnings announcement at 4:00 p.m. Eastern time on September 19, 2000. The live webcast may be accessed on the investor relations section of Pharsight’s website: http://www.pharsight.com.

Pharsight Corporation (Nasdaq: PHST) develops and markets integrated products and services that help pharmaceutical and biotechnology companies improve the drug development process. Its solution combines proprietary computer-based simulation, statistical and data analysis tools with the sciences of pharmacology, drug and disease modeling, human genetics, biostatistics and strategic decision-making.

This press release contains forward-looking statements regarding Pharsight`s expectations as to its ability to continue penetration of major pharmaceutical developers and other customers. Actual results may differ as a result of numerous risks and uncertainties, including the risk that customers will not perceive the benefits of Pharsight`s products and services to be the same as Pharsight perceives them, and the risk that customers may develop their own capabilities and therefore not require Pharsight`s products and services. This press release also contains forward-looking statements regarding the timing of the release of Pharsight`s clinical workbench product. Actual results may differ as a result of risks and uncertainties, including the risk that unexpected technical difficulties may arise regarding the finalization of the clinical workbench product, thereby delaying its release.

- Financial Tables Follow –



PHARSIGHT CORPORATION
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

[Badagry]

Hallo,
endlich finde ich hier im Board mal ein paar gewitzte Leute, die das Wahnsinnspotenzial von guten US-Bioemmissionen erkannt haben. Besitze schon unter anderem Genomic Solutions (GNSL) und Paradigm (PDGM) und bin bei meinen IPO-Forschungen unter anderem auch auf Pharsight gestossen. Das Ganze hört sich wirklich interessant an und ich denke genau wie ihr, dass hier noch viel Potenzial schlummert. Werde mir Montag mal eine kleine Position zulegen. Während andere noch schlafen sollten wir agieren!!! Habe übrigens noch 3 andere superinteressante Werte (alles IPO`s der letzen Zeit) auf meiner Watchlist. Es handelt sich um Versicor (VERS), Genaissance Pharma (GNSC) und Atherogenics (AGIX). Hat sich jemand schon genauer mit diesen Werten befasst?

[FLOTSAM_AND_JETSAM_US]

Pharsight (WpKn 940898) (PHST) aktuell + 40 % aufgrund einer Zusammenarbeit mit MLNM.


Millennium and Pharsight Sign Agreement for Application Of Pharsight`s Model- Based Software and Methodologies to Millennium`s Head Oncology Program
Jump to first matched term

-- Companies to Utilize Technology-Based Processes to Enhance Clinical Development Productivity --

CAMBRIDGE, Mass., and MOUNTAIN VIEW, Calif., July 17 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Pharsight Corporation (Nasdaq: PHST) today announced that the two companies have entered into an agreement to evaluate and apply Pharsight`s computer-assisted trial design and decision making methodologies, to Millennium`s drug development programs. The move further expands Millennium`s expertise in downstream product development by providing the company with access to Pharsight`s clinical modeling capabilities, trial design and simulation software, and database tools to improve the clinical decision-making process. Initial phases of the agreement will focus on testing and validating the utility of Pharsight`s modeling and simulation software in Millennium`s lead program for LDP-341, a novel cancer treatment currently in Phase II clinical trials.

Under terms of the agreement, Pharsight will provide Millennium with tools, software and custom consulting services to develop and apply modeling and simulation into Millennium`s development pipeline. Initially, the agreement will focus on the evaluation and validation of methodologies in the LDP-341 clinical program, with an option to expand this initial phase to include an additional unspecified product program identified by Millennium. Pending successful completion of these activities, the agreement may be extended to include deployment of Pharsight`s methodologies across an entire therapeutic area and its application across the complete spectrum of Millennium`s oncology, inflammation and metabolic disease drug development programs. Financial terms were not disclosed.

Clinical trial modeling and simulation methodologies are new approaches used in the drug development process. These approaches are helping to achieve greater efficiency and improve the timeliness of the drug development process through the evaluation of different development strategies, optimization of the design and analysis of clinical trials, and support in the selection of optimal dosing regimens for patients and patient populations. These methodologies allow pharmaceutical companies to rapidly identify those scientific, clinical and commercial variables in drug development to which the ultimate value of a given compound are most sensitive, and where uncertainties around those variables are greatest. This enables the design of a development program (series of trials) to systematically reduce those uncertainties and optimize the design of individual trials within that program. Comprehensive application of Pharsight`s methodologies therefore assists pharmaceutical companies in developing drugs more rapidly and minimizing late-stage attrition of unpromising compounds.

"Millennium has always been at the forefront of applying integrated technologies and software solutions to increase productivity in drug discovery and development," said Michael R. Pavia, Ph.D., chief technology officer at Millennium. "We look forward to working with Pharsight in support of Millennium`s commitment to enhance our downstream decision-making processes which in turn should provide overall productivity gains."

"Increasingly, biopharmaceutical leaders have come to recognize the benefits of a systematic, quantitative approach to clinical trial design, data analysis and decision-making," said Arthur Reidel, president and chief executive officer at Pharsight. "With the wealth of new drug candidates being generated by Millennium`s comprehensive discovery platform, we believe our computer-based development solutions will be beneficial in prioritizing compounds and determining which development paths offer the highest value. We believe this agreement offers both Pharsight and Millennium the opportunity to improve upon the existing models while advancing the overall productivity of the clinical trial process."

About Millennium

Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Mass., Millennium currently employs more than 1,500 people.

About Pharsight

Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers` development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at http://www.pharsight.com.